Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Biogen to buy Reata for $7.3 billion

by Rick Mullin
August 10, 2023 | A version of this story appeared in Volume 101, Issue 26

 

Biogen is acquiring Texas-based Reata Pharmaceuticals, a specialist in therapies that regulate cellular metabolism and inflammation in neurologic disease, for $7.3 billion. Reata’s Skyclarys, recently approved by the US Food and Drug Administration, is the first treatment for Friedreich’s ataxia, an inherited disease that causes progressive damage to the nervous system. Biogen CEO Christopher Viehbacher says in an announcement that Skyclarys complements Biogen’s portfolio of treatments for neuromuscular and rare diseases.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.